SCHEMBL19948905

SCHEMBL19948905

Cc1cc(CN(C)C(=O)O)cc(F)c1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 4/20 0.31
RAB9A P51151 4/20 0.31
LIPG Q9Y5X9 1/20 0.31
ROCK1 Q13464 1/20 0.31
CA12 O43570 1/20 0.31
CA9 Q16790 1/20 0.31
TDP1 Q9NUW8 1/20 0.30
HPGD P15428 1/20 0.30
F2 P00734 1/20 0.30
F11 P03951 1/20 0.30
PRSS1 P07477 1/20 0.30
PRSS2 P07478 1/20 0.30
PRSS3 P35030 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19950211 0.84 TDP1 (0.31) TDP1HPGD
SCHEMBL19949377 0.84 BACE1 (0.40)
SCHEMBL29446102 0.84 BACE1 (0.40)
SCHEMBL18485841 0.79 TDP1 (0.36) ALDH1A1KMT2AMEN1KDM4ENPC1
SCHEMBL24753989 0.78 BACE1 (0.35)
SCHEMBL19950411 0.76 MEN1 (0.38) KMT2AMEN1KDM4ELIPGROCK1
SCHEMBL19950334 0.76 BACE1 (0.40)
SCHEMBL19948906 0.73 TOP2A (0.32) KMT2AMEN1NPC1RAB9A
SCHEMBL19949123 0.73 KMT2A (0.39) ALDH1A1KMT2AMEN1KDM4ENPC1
SCHEMBL1684669 0.73 LIPG (0.53) NPC1RAB9ALIPGCA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891388-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2024-02-06 US disclosed
US-11866426-B2 Benzothiazole compounds and uses thereof INCYTE CORPORATION (US) 2024-01-09 US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2023-01-03 US disclosed
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-07-21 US disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 EP disclosed
US-11242343-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2022-02-08 US disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 US disclosed
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-02 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
US-20190076401-A1 CYANOINDAZOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-03-14 US disclosed
WO-2019051199-A1 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS INCYTE CORPORATION (US) 2019-03-14 WO disclosed
WO-2018049214-A9 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-10-18 WO disclosed
WO-2018049214-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049200-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049152-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885KMT2A 4050/4885MEN1 2805/4885
US-11242343-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885KMT2A 4050/4885MEN1 2805/4885
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 ALDH1A1 2137/4885KMT2A 3681/4885MEN1 2972/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885KMT2A 4050/4885MEN1 2805/4885
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885KMT2A 4050/4885MEN1 2805/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885KMT2A 4050/4885MEN1 2805/4885
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885KMT2A 4050/4885MEN1 2805/4885
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof PDXK, PCK1, PDK2 ALDH1A1 2137/4885KMT2A 3681/4885MEN1 2972/4885
US-11891388-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885KMT2A 4050/4885MEN1 2805/4885
US-11866426-B2 Benzothiazole compounds and uses thereof PDXK, PCK1, HIPK1 ALDH1A1 2634/4885KMT2A 3450/4885MEN1 3583/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885KMT2A 4050/4885MEN1 2805/4885
US-20190076401-A1 CYANOINDAZOLE COMPOUNDS AND USES THEREOF PCK1, PDXK, PHKG1 ALDH1A1 3266/4885KMT2A 4248/4885MEN1 2795/4885
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 ALDH1A1 2137/4885KMT2A 3681/4885MEN1 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.